151763-75-6Relevant articles and documents
BIFUNCTIONAL COMPOUND AND ITS USE IN IMMUNOTHERAPY
-
, (2021/02/12)
The invention relates to a bifunctional compound that is, on one side, an agonist of the TLR4 and, on the other side, an important inhibitor of the PSMA. Said compound is useful in immunotherapy for the treatment and/or prevention of prostate cancer. Therefore, the invention also relates to the use of the compound and to the pharmaceutical composition comprising it.
BETA-LACTONE COMPOUNDS
-
Page/Page column 11-12; 22, (2009/05/28)
The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R1 comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.
Highly enantioselective hydrogenation of β-alkyl and β-(ω-chloroalkyl) substituted β-keto esters
Karame, Iyad,Bellur, Esen,Rotzoll, Sven,Langer, Peter,Fischer, Christine,Holz, Jens,Boerner, Armin
, p. 1067 - 1076 (2008/02/01)
Highly enantioselective hydrogenation of β-alkyl and β-(ω-chloroalkyl) substituted β-keto esters was achieved with Ru catalysts based on chiral diphosphines in EtOH at 50°C under 50-bar initial hydrogen pressure, affording the corresponding β-hydroxy esters in >98% ee. Copyright Taylor & Francis Group, LLC.